Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
NASDAQ:CYTO
Price:
0.1198
USD
-60.07%
Market Closed
Market Cap:
$300k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
CH |
|
D
|
Daqian Ecology&Environment Group Co Ltd
SSE:603955
|
CN |
Income Statement
Earnings Waterfall
Altamira Therapeutics Ltd
Altamira Therapeutics Ltd
Income Statement
Altamira Therapeutics Ltd
Altamira Therapeutics Ltd
Currency: CHF
| Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
+2 033%
|
0
-76%
|
0
N/A
|
0
-39%
|
0
-67%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(3)
|
(1)
|
(1)
|
(0)
|
0
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(1)
-590%
|
(0)
+85%
|
(0)
-44%
|
(0)
+95%
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||||||||
| Operating Expenses |
(25)
|
(26)
|
(31)
|
(22)
|
(24)
|
(28)
|
(30)
|
(31)
|
(31)
|
(30)
|
(31)
|
(30)
|
(30)
|
(27)
|
(25)
|
(24)
|
(21)
|
(18)
|
(16)
|
(11)
|
(8)
|
(7)
|
(6)
|
(5)
|
(9)
|
(13)
|
(16)
|
(13)
|
(28)
|
(2)
|
(1)
|
|
| Selling, General & Administrative |
(4)
|
(4)
|
(5)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(4)
|
(5)
|
(4)
|
(3)
|
(3)
|
(4)
|
(6)
|
(8)
|
(6)
|
(8)
|
(0)
|
0
|
|
| Research & Development |
(22)
|
(22)
|
(26)
|
(18)
|
(20)
|
(24)
|
(26)
|
(26)
|
(26)
|
(25)
|
(25)
|
(25)
|
(25)
|
(22)
|
(20)
|
(19)
|
(16)
|
(13)
|
(11)
|
(7)
|
(3)
|
(3)
|
(3)
|
(3)
|
(5)
|
(7)
|
(9)
|
(7)
|
(21)
|
(2)
|
(1)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
|
| Operating Income |
(25)
N/A
|
(26)
-1%
|
(31)
-22%
|
(22)
+29%
|
(24)
-6%
|
(28)
-20%
|
(30)
-5%
|
(31)
-4%
|
(31)
-1%
|
(30)
+2%
|
(31)
-1%
|
(30)
+1%
|
(30)
0%
|
(27)
+10%
|
(25)
+7%
|
(24)
+4%
|
(21)
+13%
|
(18)
+13%
|
(16)
+15%
|
(11)
+30%
|
(8)
+30%
|
(7)
+5%
|
(6)
+23%
|
(5)
+5%
|
(9)
-77%
|
(13)
-42%
|
(17)
-28%
|
(13)
+25%
|
(29)
-125%
|
(2)
+93%
|
(1)
+74%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
2
|
4
|
3
|
2
|
2
|
1
|
1
|
2
|
(0)
|
(1)
|
0
|
0
|
0
|
1
|
4
|
4
|
4
|
0
|
(3)
|
0
|
0
|
(3)
|
(3)
|
(0)
|
0
|
(0)
|
(1)
|
(0)
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
(1)
|
(13)
|
(1)
|
(0)
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
|
| Pre-Tax Income |
(25)
N/A
|
(26)
-1%
|
(29)
-13%
|
(18)
+37%
|
(20)
-12%
|
(26)
-29%
|
(28)
-7%
|
(30)
-5%
|
(31)
-3%
|
(28)
+8%
|
(31)
-10%
|
(31)
0%
|
(30)
+2%
|
(27)
+10%
|
(25)
+7%
|
(24)
+4%
|
(18)
+27%
|
(15)
+13%
|
(12)
+20%
|
(11)
+9%
|
(10)
+9%
|
(7)
+34%
|
(6)
+18%
|
(8)
-46%
|
(12)
-50%
|
(17)
-38%
|
(18)
-3%
|
(27)
-51%
|
(31)
-17%
|
(2)
+93%
|
(0)
+94%
|
|
| Net Income | ||||||||||||||||||||||||||||||||
| Tax Provision |
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
|
| Income from Continuing Operations |
(26)
|
(26)
|
(29)
|
(18)
|
(20)
|
(26)
|
(28)
|
(30)
|
(31)
|
(28)
|
(31)
|
(31)
|
(30)
|
(27)
|
(25)
|
(24)
|
(18)
|
(15)
|
(12)
|
(12)
|
(10)
|
(7)
|
(6)
|
(8)
|
(12)
|
(17)
|
(18)
|
(27)
|
(31)
|
(2)
|
(0)
|
|
| Net Income (Common) |
(26)
N/A
|
(26)
-1%
|
(29)
-13%
|
(18)
+38%
|
(20)
-12%
|
(26)
-29%
|
(28)
-7%
|
(30)
-5%
|
(31)
-3%
|
(28)
+8%
|
(31)
-10%
|
(31)
+0%
|
(30)
+2%
|
(27)
+10%
|
(25)
+7%
|
(24)
+3%
|
(18)
+27%
|
(15)
+13%
|
(12)
+20%
|
(12)
+7%
|
(10)
+11%
|
(7)
+35%
|
(6)
+14%
|
(8)
-44%
|
(12)
-50%
|
(17)
-39%
|
(18)
-3%
|
(27)
-51%
|
(32)
-22%
|
(2)
+93%
|
(0)
+100%
|
|
| EPS (Diluted) |
-2 571
N/A
|
-4 301.77
-67%
|
-2 921
+32%
|
-1 819
+38%
|
-2 037
-12%
|
-2 634
-29%
|
-2 819
-7%
|
-2 971
-5%
|
-3 055
-3%
|
-2 802
+8%
|
-3 070
-10%
|
-3 066
+0%
|
-3 016
+2%
|
-2 714
+10%
|
-2 526
+7%
|
-2 441
+3%
|
-1 775.99
+27%
|
-771.5
+57%
|
-248
+68%
|
-287.5
-16%
|
-93.36
+68%
|
-44.2
+53%
|
-24.73
+44%
|
-27.33
-11%
|
-19.82
+27%
|
-25.84
-30%
|
-22.87
+11%
|
-29.15
-27%
|
-154.67
-431%
|
-1.43
+99%
|
0
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
